Vivani Medical (Nasdaq:VANI) today announced a new agreement with Novo Nordisk to evaluate the NPM-139 long-term semaglutide implant. NPM-139 utilizes the Alameda, California-based company's NanoPortal platform technology, under development for … [Read More...] about Vivani, Novo Nordisk partner to evaluate long-term semaglutide implant
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance
MiniMed (Nasdaq: MMED) today reported Street-beating first-quarter revenue, upping its full-year sales guidance as it notched an early European regulatory win. The Northridge, California–based diabetes tech company, spun out of Medtronic earlier … [Read More...] about MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance
Abbott wins FDA authorization for dual glucose-ketone sensor
Abbott (NYSE:ABT) announced today that the FDA has authorized its dual glucose-ketone sensing technology for people with diabetes. The authorization of the Libre Duo 10 Day system — which provides 10 days of wear time — comes three months after … [Read More...] about Abbott wins FDA authorization for dual glucose-ketone sensor
FDA clears Roche’s Alzheimer’s blood test for rule-in and rule-out assessment
Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that the FDA has cleared its Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test that identifies amyloid pathology associated with Alzheimer's disease. The test is cleared for people 55 and … [Read More...] about FDA clears Roche’s Alzheimer’s blood test for rule-in and rule-out assessment
MiniMed Flex now integrated with Abbot’s Instinct sensor
MiniMed (Nasdaq: MMED) announced that the MiniMed Flex system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott. The MiniMed Flex system is MiniMed's smallest and only app-controlled insulin pump. According to the … [Read More...] about MiniMed Flex now integrated with Abbot’s Instinct sensor
Senseonics sees activist investor take a major stake
Activist investor Sessa Capital has taken a sizeable stake in long-term, implantable CGM company Senseonics (NYSE: SENS), according to an SEC Schedule 13G filed today. The SEC filing lists Sessa directly owning 4,437,532 shares of Senseonics … [Read More...] about Senseonics sees activist investor take a major stake
Abbott, Google to deliver glucose insights through artificial intelligence
Abbott (NYSE: ABT) is turning to Google’s artificial intelligence expertise to leverage more glucose insights for users of the Abbott Park, Illinois–based life science giant’s Lingo biowearable. Under a multiyear agreement announced today, ongoing … [Read More...] about Abbott, Google to deliver glucose insights through artificial intelligence
Senseonics more than doubles Q2 revenue in post-Ascensia era
Senseonics (NYSE:SENS) stock is up more than 26% today after it reported what CEO Tim Goodnow described as the strongest quarter in the implantable, long-term CGM company's history. BTIG analysts Marie Thibault, Alexandra Pang, and Sam Eiber … [Read More...] about Senseonics more than doubles Q2 revenue in post-Ascensia era
6 diabetes tech companies you need to know
You may already know a lot of the names that are considered leaders of the diabetes technology industry. The likes of Abbott and Dexcom are leaders in the continuous glucose monitor (CGM) space. MiniMed, Insulet and Tandem Diabetes Care are a few … [Read More...] about 6 diabetes tech companies you need to know
Tandem Diabetes Care seeing early benefits of new pay-as-you-go model
Tandem Diabetes Care (Nasdaq: TNDM) says U.S. sales of its insulin pumps were boosted by a scaled pay-as-you-go reimbursement model that's been rolling out this year. According to the San Diego–based company's second-quarter report, released after … [Read More...] about Tandem Diabetes Care seeing early benefits of new pay-as-you-go model
The 10 largest diabetes tech companies in the world in 2026
Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space's largest companies? Within the last 12 months, we've seen one of the industry's biggest players separate from its parent … [Read More...] about The 10 largest diabetes tech companies in the world in 2026
In case you missed it
- Diabetes Technology Innovations Special Report — 2026
- Insulet slightly lowers 2026 sales growth outlook despite Q2 beats
- Modular Medical to initiate first phase of Pivot pump launch in October
- Dexcom Q2 results beat expectations, lead to increased sales outlook
- GLP-1 therapies delivered by Stevanato Group pen injectors get green light in Europe
- Beta Bionics posts Q2 beats on 38% sales growth
- Micron Biomedical picks up $4.5M government contract for drug delivery patch
- MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector
- FDA selects Dexcom for new digital health device pilot
- Trinity Biotech inks partnership to pair CGM+ with drug delivery system
- MiniMed says Flex insulin pump is now available through Medicare
- Inside the first-of-its-kind Enable Injections enFuse drug delivery wearable
- Medtrum to bring 300U tubeless insulin patch pump to Germany
- Modular Medical inks IMO Health collab for insulin pump EHR integration
- Abbott to launch Libre Duo dual sensor internationally in the fall, expects future reimbursement catalysts
Clinical Trials
Vivani, Novo Nordisk partner to evaluate long-term semaglutide implant
Vivani Medical (Nasdaq:VANI) today announced a new agreement with Novo Nordisk to evaluate the NPM-139 long-term semaglutide implant. NPM-139 utilizes the Alameda, California-based company’s NanoPortal platform technology, under development for chronic weight management. Vivani designed NanoPortal technology to steadily deliver medication over extended periods of time. The company aims to guarantee correct doses for patients while […]
Trinity Biotech reports positive clinical findings for next-gen CGM
Trinity Biotech (Nasdaq:TRIB) today announced new clinical findings supporting its next-generation continuous glucose monitor (CGM). Dublin, Ireland-based Trinity unveiled the CGM+ next-gen wearable biosensor in July 2025. With CGM+, the company aims to take on the growing AI wearables market. The company said it has the system in the later stages of device development. The new […]
Terrestrial Bio doses first patients in GLP-1 patch trial
Terrestrial Bio announced today that it dosed the first patients in a Phase I clinical trial evaluating its patch that delivers GLP-1 therapeutic semaglutide. Boston-based Terrestrial (formerly Vaxess Technologies) is evaluating VX-201, a needle-free microarray patch (MAP) in the trial. The company designed its MAP technology features a soluble microarray with tips that gradually dissolve into […]
Airiver treats first patient in drug-coated balloon study for chronic rhinosinusitis
Airiver Medical today announced the successful treatment of the first patient in a pivotal clinical trial of its drug-coated balloon (DCB). The first patient received treatment for chronic rhinosinusitis (CRS) in its RESTORE-2 U.S. pivotal clinical trial. It evaluates the Brooklyn Park, Minnesota-based company’s Airiver ESSpand sinus DCB. Dr. Andrew Gould treated the first patient […]
The biggest diabetes tech news out of ADA 2026
The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]
